Medicine and Dentistry
Idiopathic Pulmonary Fibrosis
100%
Patient
98%
Interstitial Lung Disease
59%
Therapeutic Procedure
56%
Lung
42%
Nintedanib
39%
Diagnosis
31%
Pirfenidone
26%
COVID-19
21%
Mortality
20%
Diseases
19%
Drug
18%
Chemotherapeutic Agent
18%
Diesel Exhaust
17%
Forced Vital Capacity
15%
Clinical Trial
12%
Silo-Filler's Disease
12%
Experience
11%
Toll Like Receptor
10%
Inpatient
10%
Serositis
10%
Morbidity
8%
Biological Marker
8%
Disease Exacerbation
7%
Heart Failure
7%
Placebo
7%
Chronic Obstructive Pulmonary Disease
7%
Deterioration
7%
Monocyte
7%
Coughing
7%
Respiratory Disease
7%
Symptom
7%
Adverse Event
7%
Macrophage
7%
Researcher
7%
Survival
6%
Comprehension
6%
Cardiovascular Disease
6%
Pathogen
6%
Infection
6%
Bronchoscopy
6%
Age
6%
Phenotype
6%
Scar Formation
6%
Sarcoidosis
6%
Granulomatosis with Polyangiitis
5%
Hand-Schüller-Christian Disease
5%
Intensive Care Unit
5%
Follow up
5%
Pulmonary Fibrosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrosing Alveolitis
38%
Nintedanib
33%
Pirfenidone
28%
Clinical Trial
21%
Interstitial Lung Disease
19%
Drug
12%
Diseases
11%
Mortality
10%
Chronic Obstructive Lung Disease
6%
Side Effect
6%
Lung Disease
6%
Cardiovascular Disease
5%
Heart Failure
5%
Adverse Event
5%
Disease Exacerbation
5%
Nursing and Health Professions
Fibrosing Alveolitis
23%
Interstitial Lung Disease
20%
Patient
18%
Forced Vital Capacity
11%
Pirfenidone
10%
Deterioration
7%
Drug
6%
Spirometry
5%
Inpatient
5%